Pfizer and DNDi ink deal for three neglected diseases
This article was originally published in Scrip
Executive Summary
Pfizer has signed an agreement with the Drugs for Neglected Disease initiative (DNDi) to assess potential compounds which could lead to new treatments for three neglected tropical diseases.